Merck acquires Modifi Biosciences

Data from Gardasil 9 studies reinforce importance of gender-neutral HPV vaccination in adults

Clinical and real-world data for the 9-valent human papillomavirus vaccine, Gardasil 9, evaluating the burden and incidence of certain HPV-related cancers and diseases, were presented at the International Papillomavirus Conference 2024 in Edinburgh, UK, from Nov. 12-15.

November 15, 2024

Vol.50 No.43

Regulatory News

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitors
Vote may lead to rollback of some indications held by BMS and Merck

The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated as a first-line treatment for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.

Adjuvant Keytruda prolongs DFS in high-risk bladder cancer

Results from a large phase III clinical trial show that treatment with Keytruda (pembrolizumab) may nearly double the length of time people with high-risk muscle-invasive bladder cancer are cancer-free following surgical removal of the bladder.

September 20, 2024

Vol.50 No.35

Clinical Roundup

Adjuvant treatment with cancer vaccine + Keytruda shows continued improvement in RFS and DMFS in resected high-risk advanced melanoma

Follow-up data from the phase IIb randomized KEYNOTE-942/mRNA-4157-P201 study, a clinical trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy, in combination with Keytruda in patients with resected high-risk melanoma (stage 3/4) following complete resection.

September 20, 2024

Vol.50 No.35

Drugs & Targets

FDA approves Keytruda + pemetrexed + chemo in first-line mesothelioma indication

FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma.

September 20, 2024

Vol.50 No.35

Drugs & Targets

Daiichi Sankyo, Merck collaborate to develop and commercialize MK-6070, an investigational delta-like ligand 3 targeting T-cell engager

Daiichi Sankyo and Merck have expanded their existing global co-development and co-commercialization agreement for three investigational DXd antibody-drug conjugates to include Merck’s MK-6070, an investigational delta-like ligand 3 targeting T-cell engager.

August 09, 2024

Vol.50 No.32

Merck acquires Modifi Biosciences

YOU MAY BE INTERESTED IN

Data from Gardasil 9 studies reinforce importance of gender-neutral HPV vaccination in adults

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitors
Vote may lead to rollback of some indications held by BMS and Merck

Adjuvant Keytruda prolongs DFS in high-risk bladder cancer

Adjuvant treatment with cancer vaccine + Keytruda shows continued improvement in RFS and DMFS in resected high-risk advanced melanoma

FDA approves Keytruda + pemetrexed + chemo in first-line mesothelioma indication

Daiichi Sankyo, Merck collaborate to develop and commercialize MK-6070, an investigational delta-like ligand 3 targeting T-cell engager

Renew today!

Subscriber content

Login

Merck acquires Modifi Biosciences

YOU MAY BE INTERESTED IN

Data from Gardasil 9 studies reinforce importance of gender-neutral HPV vaccination in adults

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitorsVote may lead to rollback of some indications held by BMS and Merck

Adjuvant Keytruda prolongs DFS in high-risk bladder cancer

Adjuvant treatment with cancer vaccine + Keytruda shows continued improvement in RFS and DMFS in resected high-risk advanced melanoma

FDA approves Keytruda + pemetrexed + chemo in first-line mesothelioma indication

Daiichi Sankyo, Merck collaborate to develop and commercialize MK-6070, an investigational delta-like ligand 3 targeting T-cell engager

Login

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitors
Vote may lead to rollback of some indications held by BMS and Merck